Pharsight

Nourianz generic

Nourianz is an anti-parkinson's drug owned by Kyowa Kirin. It contains the active ingredient istradefylline and was first authorized for market use on August 27, 2019. The drug has a total of 4 patents, with 1 already expired.

When will Nourianz generic be available?

The generic version of Nourianz could potentially be released after January 28, 2028, when the last patent (US7727993) expires. However, drug patent challenges against Nourianz can be filed from August 28, 2023.

Nourianz uses

Nourianz is primarily used for reducing off time from l-dopa therapy in Parkinson's disease patients. The active ingredient, istradefylline, effectively treats movement disorders and helps to reduce or suppress side effects of Parkinson's disease therapy.

Nourianz patent expiration

Nourianz has a total of 4 drug patents, out of which 1 has expired. The remaining patents, including the ones with expiry dates in 2024, 2027 and 2028, still provide protection for Nourianz. The expiry date of the last patent is January 28, 2028. Below are the details of the patents related to Nourianz generic:

Nourianz dosage

Want to ask something?